Harbor Biosciences’ (Nasdaq: HRBR) 45% HIGHER; apoptone(R) for prostate cancer shows partial overall response in an ongoing Phase I/IIA clinical trial. According to the most recent results, one patient in the 350 mg group confirmed a partial overall response to the disease, however, the median time to progression was not reached. For the 100 mg cohort however, the TTP was 24 weeks.

C&D Technologies, Inc. (NYSE: CHP) 10% HIGHER; reports Q2 adjusted loss of $0.19, cents better than the analyst estimate of ($0.06). Revenue for the quarter was $83.8 million, which compares to the estimate of $91.0 million. Also